UK markets closed

Achiko AG (ACHKF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
0.20000.0000 (0.00%)
At close: 10:13AM EST
Full screen
Trade prices are not sourced from all markets
Previous close0.2000
Open0.2000
BidN/A x N/A
AskN/A x N/A
Day's range0.2000 - 0.2000
52-week range0.2000 - 0.4123
Volume32,500
Avg. volume539
Market cap23.797M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-0.1230
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Achiko AG Announces Feature Article on “How We Get Back to Normal” with its AptameX™ Covid-19 Rapid Test Technology

    ZURICH, Switzerland, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Achiko AG (OTCQB: ACHKF; SIX: ACHI; ISIN CH0522213468) (“Achiko”, the “Company”) is pleased to announce a feature article in The Jakarta Post: “How we get back to normal: Restoring Trust and Confidence through Testing with AptameX” which discusses how Achiko is contributing to provide affordable and accurate testing to Indonesia with its Covid-19 saliva-based rapid test AptameX™, which fills the gap between rapid tests and PCR testing. The a

  • EQS Group

    Achiko AG Announces Feature Article on How We Get Back to Normal with its AptameXTM Covid-19 Rapid Test Technology

    EQS-News: Achiko AG / Key word(s): Miscellaneous17.01.2022 / 14:08 Achiko AG Announces Feature Article on How We Get Back to Normal with its AptameXTM Covid-19 Rapid Test TechnologyZurich, 17 January 2022- Achiko AG (SIX: ACHI; OTCQB: ACHKF; ISIN CH0522213468) ("Achiko", the "Company") is pleased to announce a feature article in The Jakarta Post: "How we get back to normal: Restoring Trust and Confidence through Testing with AptameX" which discusses how Achiko is contributing to provide affordab

  • Globe Newswire

    Achiko AG Reports Breakthrough Calibration Results for its AptameX™ Covid-19 Rapid Test Technology

    AptameX™ Covid-19 rapid calibration successfully classified 100% of results indicatinga likely > 97% Sensitivity and > 97% Specificity result in the first-generation test kits.Results were demonstrable both at CT values under 25, and between 25 to 33, indicating superior test performance to other rapid tests.Achiko is now moving to scale production and completing CE Mark to respond to global demand. ZURICH, Switzerland, Jan. 14, 2022 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR